Ikano Therapeutics is a specialty pharmaceutical company focused on developing Midazolam Nasal Spray (USL261) for acute repetitive seizures. Ikano was acquired by UCB.
Sector: Life Sciences
Innovent Biologics
Innovent Biologics (1801.HK) has built a robust pipeline of innovative and commercially promising monoclonal antibodies and other biologics in the fields of oncology, ophthalmology, autoimmune, and cardiovascular diseases.
Hua Medicine
Hua Medicine (2552.KHK) is a leading clinical-stage, innovative drug development company in China, focused on novel therapies for the treatment of diabetes and CNS disorders.
Hile BioPharma
Hile (603718.SS) is a leading animal vaccine manufacturer that specializes in sales, marketing and commercialization of animal vaccine products in China.
FoldRx
FoldRx Pharmaceuticals focuses on creating disease modifying drug therapies for diseases of protein misfolding. FoldRx developed, tafamidis, the first-in-class therapy approved or TTR amyloidosis. FoldRx was acquired by Pfizer.
Dimension Therapeutics
Dimension Therapeutics was a leader in the development of AAV (adeno-associated virus) gene therapies for rare disease. Dimension Therapeutics was acquired by Ultragenyx Pharmaceuticals (NASDAQ: RARE).
Coherus Biosciences
Coherus Biosciences (NASDAQ: CHRS) is a biosimilar-focused, biologics platform company with the cutting-edge analytics, process science, and clinical and regulatory capabilities to develop and commercialize high-quality biosimilar therapeutics worldwide.
CardioKine
CardioKine is a pharmaceutical company focused on the development of lixivaptan, an oral compound under development for the potential treatment of hyponatremia in patients with congestive heart failure. CardioKine was acquired by Cornerstone Therapeutics.
Blueprint Medicines
Blueprint Medicines (NASDAQ: BPMC) is a precision therapy company striving to improve human health. Blueprint Medicines was acquired by Sanofi in 2025.
Bikam Pharmaceuticals
Bikam Pharmaceuticals is a drug discovery company focused on developing novel therapies for diseases of the eye with exceptionally high unmet medical need. Bikam Pharmaceuticals was acquired by Shire.